{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:20:16Z","timestamp":1792200016095,"version":"4.4.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40291-025-00771-z","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T09:09:56Z","timestamp":1738314596000},"page":"419-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Obecabtagene Autoleucel: First Approval"],"prefix":"10.1007","volume":"29","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,31]]},"reference":[{"issue":"1","key":"771_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","volume":"112","author":"A Khan","year":"2024","unstructured":"Khan A, Asija S, Pendhari J, et al. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for? Eur J Haematol. 2024;112(1):6\u201318.","journal-title":"Eur J Haematol"},{"key":"771_CR2","unstructured":"US Food & Drug Administration. FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia [media release]. 8 Nov 2024."},{"key":"771_CR3","unstructured":"Autolus Therapeutics. Autolus Therapeutics announces FDA approval of AUCATZYL\u00ae (obecabtagene autoleucel \u2013 obe-cel) for adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (r\/r B-ALL) [media release]. 8 Nov 2024."},{"issue":"9","key":"771_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408\u201314.","journal-title":"Nat Med"},{"key":"771_CR5","unstructured":"Autolus Therapeutics. AUCATZYL\u00ae (obecabtagene autoleucel) suspension for intravenous infusion: US Prescribing information. 2024. https:\/\/www.autolus.com\/media\/aj4olbsd\/aucatzyl-pi-08-nov2024.pdf. Accessed 11 Nov 2024"},{"key":"771_CR6","unstructured":"Autolus. Autolus announces license agreement with UCL Business PLC for clinical-stage product candidate in development for the treatment of B-cell malignancies [media release]. 23 Apr 2018."},{"key":"771_CR7","unstructured":"Autolus Therapeutics. Autolus Therapeutics to receive $70 million in milestone payments from Blackstone Life Sciences [media release]. 8 Dec 2022."},{"key":"771_CR8","unstructured":"Autolus Therapeutics. Autolus Therapeutics selects Cardinal Health as U.S. commercial distribution partner [media release]. 27 Apr 2023."},{"issue":"23","key":"771_CR9","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","volume":"391","author":"C Roddie","year":"2024","unstructured":"Roddie C, Sandhu KS, Tholouli E, et al. Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia. N Engl J Med. 2024;391(23):2219\u201330.","journal-title":"N Engl J Med"},{"issue":"16 Suppl","key":"771_CR10","doi-asserted-by":"publisher","first-page":"6504","DOI":"10.1200\/JCO.2024.42.16_suppl.6504","volume":"42","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Tholouli E, Sandhu K, et al. Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia (R\/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib\/II study [abstract 6504 plus presentation]. J Clin Oncol. 2024;42(16 Suppl):6504.","journal-title":"J Clin Oncol"},{"issue":"30","key":"771_CR11","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.21.00917","volume":"39","author":"C Roddie","year":"2021","unstructured":"Roddie C, Dias J, O\u2019Reilly MA, et al. Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. J Clin Oncol. 2021;39(30):3352\u201363.","journal-title":"J Clin Oncol"}],"container-title":["Molecular Diagnosis & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00771-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00771-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T20:02:24Z","timestamp":1746734544000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00771-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00771-z","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"assertion":[{"value":"25 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Arnold Lee is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and material, Code Availability"}}]}}